probiotics / IL12 Cancer Research Results

ProBio, probiotics: Click to Expand ⟱
Features:
Probiotics contain live bacteria the supplements the gastrointestinal flora. (Which can be affected from infection or antibiotics drugs.)
Some studies have suggested that gut microbiota—including Bifidobacterium species—can affect systemic immunity. This is important because the state of the immune system influences the body’s ability to fight cancer and also the response to immunotherapies.
Preclinical investigations have demonstrated that certain Bifidobacterium strains may help improve responses to immune checkpoint inhibitors in animal models.
There has been emerging research looking into discrete strains or formulations of Bifidobacterium longum (sometimes labeled with additional identifiers such as RAPO) that may have unique properties or enhanced effects.
IL12, Interleukin-12: Click to Expand ⟱
Source: HalifaxProj(induce)
Type:
IL-12, an antitumor cytokine is considered to be a promising cytokine for enhancing an antitumor immune response.
Interleukin-12 (IL-12) is a cytokine that plays a crucial role in the immune response, particularly in the activation of T cells and natural killer (NK) cells. It is produced by various immune cells, including macrophages and dendritic cells, and is known for its ability to promote the differentiation of T cells into a type that can effectively combat cancer cells.

IL-12 is often expressed in various cancers, including melanoma, renal cell carcinoma, breast cancer, and colorectal cancer. Its expression can vary depending on the tumor type and the immune context.
Tumor-infiltrating immune cells, particularly activated macrophages and dendritic cells, are significant sources of IL-12 in the tumor microenvironment.

IL-12 is primarily known for its role in promoting anti-tumor immunity. It enhances the differentiation of naive T cells into T helper 1 (Th1) cells, which produce pro-inflammatory cytokines and support cytotoxic T cell responses.
IL-12 also stimulates the activity of NK cells, enhancing their ability to kill tumor cells and produce additional cytokines, such as interferon-gamma (IFN-γ), which further promotes anti-tumor immunity.

Low levels of IL-12 in the tumor microenvironment are often associated with poor anti-tumor immune responses and can correlate with worse clinical outcomes. In such cases, strategies to enhance IL-12 production or signaling may be beneficial for improving anti-tumor immunity.
Scientific Papers found: Click to Expand⟱
5624- ProBio,  Bif,    A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer
- Trial, Testi, NA
Dose↝, TNF-α↓, IL6↓, IL10↓, IL12↓, IL22↓, toxicity↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling ⓘ

IL10↓, 1,   IL12↓, 1,   IL22↓, 1,   IL6↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IL12, Interleukin-12
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:256  Target#:157  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page